Edward J. Dulac III

CIK: 0001821530

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

NTLA

Intellia Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

NTLA
Intellia Therapeutics, Inc.
Jul 22, 2026
Sale(S)
Direct
8.1K shares at avg. $11.25$91K
NTLA
Intellia Therapeutics, Inc.
Jul 2, 2026
Sale(S)
Direct
4.7K shares at avg. $18.00$84K
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2026
Award(A)
Direct
61.3K shares-
NTLA
Intellia Therapeutics, Inc.
Jan 5, 2026
Sale(S)
Direct
6.4K shares at avg. $9.21$59K
NTLA
Intellia Therapeutics, Inc.
Jul 23, 2025
Sale(S)
Direct
7.5K shares at avg. $14.02$105K
NTLA
Intellia Therapeutics, Inc.
Mar 1, 2025
Award(A)
Direct
47.2K shares-

		Type	Shares	Price		Ownership
Jul 22, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	8,111	$11.25	$91,249	Direct
Jul 2, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	4,677	$18.00	$84,186	Direct
Mar 1, 2026	NTLA Intellia Therapeutics, Inc.	Award(A)	61,280	-	$0	Direct
Jan 5, 2026	NTLA Intellia Therapeutics, Inc.	Sale(S)	6,379	$9.21	$58,751	Direct
Jul 23, 2025	NTLA Intellia Therapeutics, Inc.	Sale(S)	7,462	$14.02	$104,617	Direct
Mar 1, 2025	NTLA Intellia Therapeutics, Inc.	Award(A)	47,200	-	-	Direct

1-6 of 6 transactions

About Dulac Edward J III

Dulac Edward J III (SEC CIK 0001821530) files insider reports with the SEC as EVP, Chief Financial Officer of Intellia Therapeutics, Inc. (NTLA).

Signal8 holds 6 ownership filings by Dulac Edward J III, all Form 4s, filed between Mar 4, 2025 and Jul 24, 2026. Those filings report 6 transactions, from Mar 1, 2025 to Jul 22, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Dulac Edward J III's filings is in CAMBRIDGE, MA.

Recent filings by Dulac Edward J III

Jul 22, 2026: Open-market sale of NTLA shares (Form 4, code S).
Jul 2, 2026: Open-market sale of NTLA shares (Form 4, code S).
Mar 1, 2026: Grant or award of NTLA shares (Form 4, code A).
Jan 5, 2026: Open-market sale of NTLA shares (Form 4, code S).
Jul 23, 2025: Open-market sale of NTLA shares (Form 4, code S).

Other insiders filing for Intellia Therapeutics, Inc. (NTLA)

Marantz Jing L., EVP, Chief Medical Officer
Dube Michael P, VP, Chief Accounting Officer
LEONARD JOHN M, President and CEO
Verwiel Frank, Director
Keresty Georgia, Director
GOODMAN JESSE, Director

How to read Form 4 transaction codes